AstraZeneca Plc raised the company’s product sales forecast for 2019 after second-quarter results beat analysts’ expectations, thanks to strong sales from cancer medicines and emerging markets, especially China.
AstraZeneca Plc beat first-quarter 2019 sales and earnings expectations as the British drugmaker benefited from a push into cancer drugs and emerging markets including China.
Sanofi will change the organizational structure of two Global Business Units to provide greater focus on operations in mature markets and across emerging markets.
Strategic Move Enhances Teva’s Presence in Mexico, the Second Largest Market in Latin America and a Major Emerging Market Brings a Portfolio of Differentiated, Patent-Protected, Fixed-Dose Medicine Combinations, Strong Brand […]
The big worries on growth hanging over the pharmaceuticals industry are poles apart. Pressure on U.S. drug pricing is casting a shadow over the sector’s most lucrative market. But slowing […]
Healthcare investment firm OrbiMed manages over $14 billion in public and private equity, nearly $1.4 billion of which is focused on Asia. With 23 private equity investments in Asia, OrbiMed […]
